Clinical Trial

The Long COVID Treatment Trial

Study acronym: LOCITT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-08-14; most recent amendment 2025-12-19.
Status change: Recruiting → Active, Not Recruiting 2025-12-19
Status change: Enrolling by Invitation → Recruiting 2025-10-31
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-10-23
Trial Details
NCT Number NCT07128082
Lead Sponsor Scripps Translational Science Institute
Collaborators: Schmidt Initiative for Long COVID
Conditions Long COVID
Enrollment 1,000 participants
Start Date 2025-10-30
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-23